Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ideaya Biosciences Inc (IDYA)

Ideaya Biosciences Inc (IDYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,842,804
  • Shares Outstanding, K 75,687
  • Annual Sales, $ 23,390 K
  • Annual Income, $ -112,960 K
  • 60-Month Beta 0.79
  • Price/Sales 123.35
  • Price/Cash Flow N/A
  • Price/Book 3.05
Trade IDYA with:

Options Overview Details

View History
  • Implied Volatility 74.62% ( +8.65%)
  • Historical Volatility 42.03%
  • IV Percentile 86%
  • IV Rank 53.68%
  • IV High 103.54% on 07/06/23
  • IV Low 41.11% on 12/05/23
  • Put/Call Vol Ratio 12.00
  • Today's Volume 65
  • Volume Avg (30-Day) 46
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 1,500
  • Open Int (30-Day) 1,405

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.56
  • Number of Estimates 7
  • High Estimate -0.49
  • Low Estimate -0.62
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.57 +4.78%
on 05/29/24
42.20 -11.68%
on 05/21/24
-3.23 (-7.98%)
since 05/17/24
3-Month
35.57 +4.78%
on 05/29/24
46.40 -19.68%
on 03/21/24
-6.19 (-14.24%)
since 03/18/24
52-Week
20.90 +78.33%
on 07/27/23
47.74 -21.92%
on 02/15/24
+13.20 (+54.84%)
since 06/16/23

Most Recent Stories

More News
Chart of the Day: IDEAYA Biosciences - Oncology Biomedicine

The Chart of the Day belongs to the oncology based biomedical company IDEAYA Biosciences (IDYA) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

IDYA : 37.27 (-0.77%)
Why Ideaya Biosciences Stock Is Plummeting Today

Ideaya stock is getting hit hard following a recent press release from the company.

IDYA : 37.27 (-0.77%)
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma

Proffered paper oral presentation at ESMO 2023 scheduled for Monday, October 23, 2023, at 8:50 am CEST will be presented by Dr. Meredith McKean, Sara Cannon...

IDYA : 37.27 (-0.77%)
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma

Initiated Phase 2 expansion of darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma based on preliminary clinical efficacy observed...

IDYA : 37.27 (-0.77%)
IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day

Selected a Werner Helicase Inhibitor Development Candidate in collaboration with GSK Observed monotherapy complete responses preclinically in multiple in vivo...

IDYA : 37.27 (-0.77%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted...

IDYA : 37.27 (-0.77%)
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer

Fast Track designation granted by U.S. FDA for evaluation of IDE161 in adult patients with HR+, Her2-, BRCA1/2 mutant advanced or metastatic breast cancer...

IDYA : 37.27 (-0.77%)
IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations

Fast Track designation granted by U.S. FDA for evaluation of IDE161 in adult patients with BRCA1/2 mutant advanced or metastatic ovarian cancer who are...

IDYA : 37.27 (-0.77%)
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors

Initiated IDE161 Phase 1 expansion based on preliminary tumor shrinkage observed in multiple HRD solid tumor patients, including an endometrial cancer subject...

IDYA : 37.27 (-0.77%)
Chart of the Day: IDEAYA Biosciences --- A Wing and a Prayer

The Chart of the Day belongs to the biotechnology company IDEAYA Biosciences (IDYA) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy...

IDYA : 37.27 (-0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences...

See More

Key Turning Points

3rd Resistance Point 38.27
2nd Resistance Point 38.01
1st Resistance Point 37.64
Last Price 37.27
1st Support Level 37.01
2nd Support Level 36.75
3rd Support Level 36.38

See More

52-Week High 47.74
Fibonacci 61.8% 37.48
Last Price 37.27
Fibonacci 50% 34.32
Fibonacci 38.2% 31.15
52-Week Low 20.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar